RT Journal Article
SR Electronic
T1 ISARIC Clinical Data Report 8 April 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.17.20155218
DO 10.1101/2020.07.17.20155218
A1 Merson, Laura
A1 ,
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/04/09/2020.07.17.20155218.abstract
AB ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report is a part of a series and includes the results of data analysis on 8 April 2021.We thank all of the data contributors for their ongoing support.Report highlights include Data have been entered for 340,312 individuals from 1609 sites across 54 countries.The analysis detailed in this report only includes individuals:for whom data collection commenced on or before 1 February 2021.ANDwho have laboratory-confirmed or clinically-diagnosed SARS-COV-2 infection.For the 264,496 cases who meet eligibility criteria for this report:○ The median age is 61 years.○ The five most common symptoms at admission were shortness of breath, cough, history of fever, fatigue/malaise, and altered consciousness/confusion. Children and older adults were less likely to display typical symptoms, and around 40% of patients >80 years experienced confusion.○ A total of 19% of patients were admitted at some point during their illness into an intensive care unit.○ Antibiotic use is high (79.9% of patients received antibiotics - the choice of antibiotic and specific indication have not yet been determined.)○ Altered consciousness/confusion was also relatively frequent (28,190/130,157) and most common in elderly patients. Overall, elderly patients are less likely to present with URTI symptoms.To access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below:https://isaric.org/research/covid-19-clinical-research-resources/evidence-reports/ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium)A global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseasesCOVID-19 Report: 08 April 2021 Containing data extracted 15 February 2021Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://isaric.net/ccp/ https://isaric4c.net/ Funding StatementThis work is supported by grants fincluding: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907), Wellcome Trust and Department for International Development (DID; 215091/Z/18/Z), and the Bill and Melinda Gates Foundation (OPP1209135), and Liverpool Experimental Cancer Medicine Centre for providing infrastructure support for this research (grant reference C18616/A25153). Contents of the publication are those of the authors and not necessarily reflect those of the funders. Additional funding support can be viewed at https://isaric.tghn.org/covid-19-data-management-hosting-contributors/.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee approval was given by the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central - Oxford C Research Ethics Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the UK, which represents the majority of the data. Other institutional and national approvals are in place as per local requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe welcome applications for access to data on the Data Sharing Platform via the Data Access Committee (www.iddo.org/covid-19). UK data can be requested through the ISARIC 4C Independent Data and Material Access Committee (https://isaric4c.net). https://isaric4c.net https://www.iddo.org/covid-19